BPREVALENCE OF REPORTED ESRD Reference section B Table B.2 B.2 (continued) Point prevalent rates of of reported ESRD patients patients alive alive on on December December 31 31 of of each each year, year, per per million million population, population, by by demographic demographic characteristics characteristics & primary primary diagnosis diagnosis 324 UNADJUSTED 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 0-4 20.7 20.4 20.6 21.8 20.4 21.4 22.5 24.7 24.4 23.6 22.9 5-9 39.5 40.0 40.3 40.4 43.2 41.8 42.6 42.6 44.5 46.1 47.7 10-14 70.0 74.2 77.2 79.2 77.8 81.6 81.5 84.0 84.2 87.7 85.1 15-19 143.5 146.2 149.5 150.1 152.3 152.6 157.0 158.4 162.0 163.4 169.5 20-29 380.4 393.6 403.0 413.6 418.9 424.6 425.0 422.3 418.3 410.0 403.9 30-39 754.1 790.3 816.8 845.3 871.0 898.4 925.4 945.7 959.4 976.0 990.9 40-49 1,206.3 1,272.1 1,334.2 1,392.8 1,440.1 1,493.0 1,531.8 1,569.9 1,598.1 1,626.4 1,654.4 50-59 1,846.4 1,977.5 2,072.7 2,157.5 2,238.3 2,345.5 2,447.1 2,528.4 2,621.5 2,691.1 2,760.5 60-64 2,427.4 2,636.7 2,835.5 3,028.0 3,190.0 3,353.3 3,467.2 3,606.4 3,692.2 3,793.1 3,888.9 65-69 2,696.2 2,931.5 3,102.3 3,336.5 3,560.4 3,793.2 4,044.6 4,199.6 4,388.4 4,522.0 4,643.2 70-79 2,603.0 2,882.6 3,091.6 3,350.3 3,610.4 3,824.6 4,022.9 4,229.4 4,383.7 4,598.7 4,752.7 80+ 1,602.0 1,773.2 1,925.3 2,108.9 2,305.0 2,497.4 2,683.5 2,904.8 3,053.2 3,241.0 3,395.6 0-19 66.7 68.8 70.9 72.4 73.4 74.7 76.4 78.0 79.5 81.0 82.2 20-44 678.5 711.1 739.9 766.3 788.6 811.8 831.1 843.0 851.9 857.0 863.2 45-64 1,797.2 1,922.9 2,020.5 2,120.5 2,210.4 2,314.2 2,398.7 2,478.9 2,551.3 2,619.6 2,683.8 65-74 2,710.6 2,966.0 3,147.5 3,391.3 3,630.7 3,843.2 4,057.1 4,234.7 4,413.8 4,585.9 4,736.9 75+ 1,982.0 2,200.8 2,388.0 2,610.6 2,839.2 3,053.9 3,257.1 3,466.2 3,599.9 3,791.2 3,922.9 Male 1,032.6 1,109.8 1,172.4 1,245.2 1,316.5 1,388.4 1,456.1 1,520.7 1,577.7 1,639.3 1,692.3 Female 844.7 910.4 963.9 1,020.0 1,071.5 1,125.5 1,173.0 1,219.0 1,257.6 1,295.4 1,331.9 White 716.1 767.5 807.7 855.4 901.2 946.8 992.9 1,038.7 1,077.1 1,115.8 1,150.7 Black 2,396.3 2,579.6 2,736.0 2,897.3 3,048.5 3,207.0 3,324.2 3,435.1 3,530.5 3,639.5 3,740.7 Native American 1,329.3 1,419.2 1,500.6 1,558.5 1,607.5 1,686.7 1,741.1 1,754.1 1,826.1 1,869.7 1,892.6 Asian 812.7 901.1 971.9 1,028.8 1,082.0 1,140.8 1,195.4 1,240.2 1,288.8 1,339.4 1,377.0 †Hispanic 935.3 986.7 1,035.9 1,086.3 1,138.4 1,187.8 1,236.5 1,282.6 †Non-Hispanic 1,154.6 1,218.2 1,284.0 1,343.7 1,400.7 1,449.4 1,500.2 1,545.9 Diabetes 272.0 303.0 333.1 366.1 398.5 428.9 455.1 483.0 506.6 529.8 549.1 Hypertension 249.0 269.3 276.9 287.9 298.9 311.1 323.4 334.2 344.5 356.4 368.4 Glomerulonephritis 185.1 195.1 203.1 211.6 218.8 226.1 232.3 236.9 241.0 245.2 248.1 Cystic kidney 46.6 49.0 51.3 53.2 55.1 57.7 60.1 62.4 64.4 66.6 68.7 Other urologic 27.9 28.8 31.6 34.2 36.5 38.5 40.9 42.5 43.7 45.2 46.3 Other cause 102.6 107.8 114.4 120.1 125.2 131.5 136.6 141.8 145.8 150.2 154.7 Unknown cause 43.2 45.4 46.2 47.9 49.3 51.0 53.3 55.4 57.6 59.4 61.4 Missing disease 10.3 9.4 9.4 9.4 9.3 9.6 10.2 10.9 11.3 11.9 12.6 All 936.5 1,007.8 1,065.9 1,130.2 1,191.5 1,254.3 1,311.8 1,367.1 1,414.9 1,464.5 1,509.3 The prevalent cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. Age is calculated as of December 31. U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank. *Values for cells with 10 or fewer patients are suppressed.
Table B.2 B.2 (continued) Point prevalent rates of of reported ESRD patients patients alive alive on on December December 31 31 of of each each year, year, per per million million population, population, by by demographic demographic characteristics characteristics & primary primary diagnosis diagnosis PREVALENCE OF REPORTED ESRD 2005 Annual <strong>Data</strong> ReportB ADJUSTED 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 0-4 3.9 6.1 9.2 11.5 12.4 15.3 16.5 18.0 17.7 17.8 17.1 18.3 19.0 5-9 12.9 14.1 17.3 19.3 22.4 24.4 28.1 30.0 31.6 35.2 37.2 38.5 37.9 10-14 30.5 33.1 38.7 44.1 47.3 49.8 52.3 56.1 59.3 60.5 64.3 65.3 67.5 15-19 70.7 78.6 85.8 90.0 95.2 102.3 107.0 114.1 119.9 126.3 129.6 134.9 138.3 20-29 160.1 174.8 192.9 210.7 225.9 241.3 257.8 272.3 289.6 307.8 326.4 340.9 358.4 30-39 291.2 330.3 369.4 411.0 452.4 487.1 523.6 556.8 591.6 629.5 662.9 697.8 730.9 40-49 436.6 490.3 541.6 620.9 678.2 732.2 781.1 836.1 904.7 989.0 1,058.1 1,145.8 1,217.0 50-59 596.6 689.5 782.6 879.2 976.2 1,062.4 1,158.3 1,255.9 1,376.6 1,509.7 1,648.4 1,792.7 1,936.0 60-64 665.6 783.8 900.6 1,060.1 1,185.3 1,314.7 1,410.5 1,566.3 1,716.9 1,897.7 2,102.7 2,300.6 2,525.2 65-69 665.1 754.9 860.0 1,056.4 1,200.1 1,330.0 1,489.9 1,695.1 1,870.9 2,073.5 2,315.8 2,592.1 2,866.1 70-79 534.6 623.2 737.1 945.3 1,091.9 1,228.0 1,396.2 1,562.9 1,746.5 1,995.7 2,238.5 2,563.3 2,857.7 80+ 185.2 227.9 291.1 413.0 491.8 605.8 720.9 857.2 988.7 1,161.2 1,381.8 1,607.3 1,855.6 0-19 29.5 33.0 37.7 41.2 44.3 47.9 51.0 54.6 57.1 60.0 62.0 64.2 65.7 20-44 261.1 290.4 322.2 359.8 391.3 420.8 453.2 479.7 512.8 549.2 584.0 617.9 652.1 45-64 582.3 675.5 765.7 876.3 973.5 1,064.1 1,146.5 1,252.5 1,369.5 1,505.9 1,643.6 1,791.4 1,937.3 65-74 641.3 728.8 839.8 1,040.8 1,184.7 1,315.7 1,482.5 1,662.5 1,840.1 2,065.1 2,327.9 2,633.6 2,921.8 75+ 274.1 333.2 412.3 563.8 666.1 788.7 919.8 1,070.1 1,220.4 1,419.0 1,633.6 1,888.7 2,149.7 325 Male 336.6 382.0 432.1 500.1 556.3 607.9 660.9 718.3 780.1 856.1 934.0 1,020.4 1,102.3 Female 234.6 268.6 303.2 350.2 387.5 425.0 465.4 509.6 557.9 613.8 669.8 731.8 794.0 White 219.4 247.4 276.9 316.4 348.3 379.6 413.3 448.9 485.2 529.2 575.0 625.4 673.0 Black 823.7 948.8 1,078.0 1,266.9 1,418.7 1,556.7 1,698.3 1,861.4 2,051.3 2,274.1 2,493.5 2,738.8 2,989.4 Native American 343.1 450.0 539.9 696.3 809.7 905.5 1,009.6 1,133.0 1,265.8 1,425.0 1,583.1 1,747.1 1,928.1 Asian 111.2 148.9 214.8 279.0 339.4 405.9 464.5 526.4 603.6 691.2 778.9 885.3 985.7 †Hispanic †Non-Hispanic Diabetes 27.2 37.9 50.8 64.3 79.6 95.1 111.6 129.4 149.0 175.4 203.5 234.5 264.7 Hypertension 49.4 62.5 78.1 94.0 108.2 121.7 136.1 151.2 168.4 189.6 209.3 230.9 253.2 Glomerulonephritis 62.7 72.5 83.4 96.3 107.9 118.3 128.0 137.8 147.6 157.8 167.2 177.1 186.1 Cystic kidney 17.5 20.1 23.1 26.5 29.2 31.6 34.0 36.6 38.8 41.1 43.6 46.2 48.7 Other urologic 7.2 9.2 11.4 13.8 16.0 18.2 19.8 21.8 23.4 24.8 25.8 27.4 28.7 Other cause 29.1 34.9 42.2 50.1 56.7 62.9 68.6 73.0 77.8 84.1 89.0 94.1 99.5 Unknown cause 29.1 31.0 31.0 32.9 34.2 34.0 35.1 36.9 38.1 38.3 39.6 41.6 43.4 Missing disease 60.5 54.0 43.9 42.6 34.9 28.6 23.4 20.0 17.9 15.0 13.7 12.5 11.1 All 282.6 322.0 363.8 420.5 466.5 510.4 556.6 606.8 661.1 726.1 791.6 864.4 935.2 Rates by age are adjusted for gender & race, rates by gender are adjusted for age & race, rates by race/ethnicity are adjusted for gender & age, rates by primary diagnosis are adusted for age, gender, & race. The prevalent cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. Age is calculated as of December 31. U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly. *Values for cells with 10 or fewer patients are suppressed. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.
- Page 1 and 2: Reference A Section Incidence of re
- Page 3 and 4: ON OUR WEBSITE & CD Incident counts
- Page 5 and 6: INCIDENCE OF REPORTED ESRD 2005 Ann
- Page 7 and 8: ON OUR WEBSITE & CD Incident rates
- Page 9 and 10: INCIDENCE OF REPORTED ESRD 2005 Ann
- Page 11 and 12: INCIDENCE OF REPORTED ESRD 2005 Ann
- Page 13 and 14: ON OUR WEBSITE & CD Incident counts
- Page 15 and 16: ON OUR WEBSITE & CD Median age at s
- Page 17 and 18: ON OUR WEBSITE & CD Incidence of re
- Page 19 and 20: ON OUR WEBSITE & CD Incident counts
- Page 21 and 22: Table A.8 A.8 (continued) Incident
- Page 23 and 24: Table A.8 A.8 (continued) Incident
- Page 25 and 26: INCIDENCE OF REPORTED ESRD 2005 Ann
- Page 27 and 28: Table A.9 A.9 (continued) Incident
- Page 29 and 30: Table A.9 A.9 (continued) Incident
- Page 31 and 32: ON OUR WEBSITE & CD Incident counts
- Page 33 and 34: INCIDENCE OF REPORTED ESRD 2005 Ann
- Page 35 and 36: Reference B Section Prevalence of r
- Page 37 and 38: ON OUR WEBSITE & CD Point prevalent
- Page 39 and 40: Table B.1 B.1 (continued) Point pre
- Page 41: ON OUR WEBSITE & CD Point prevalent
- Page 45 and 46: PREVALENCE OF REPORTED ESRD 2005 An
- Page 47 and 48: ON OUR WEBSITE & CD Point prevalent
- Page 49 and 50: ON OUR WEBSITE & CD Median age at s
- Page 51 and 52: ON OUR WEBSITE & CD Prevalence of r
- Page 53 and 54: ON OUR WEBSITE & CD Point prevalent
- Page 55 and 56: Table B.8 B.8 (continued) PREVALENC
- Page 57 and 58: Table B.8 B.8 (continued) PREVALENC
- Page 59 and 60: Table B.9 B.9 Point prevalent rates
- Page 61 and 62: Table B.9 B.9 (continued) Point pre
- Page 63 and 64: Table B.9 B.9 (continued) Point pre
- Page 65 and 66: ON OUR WEBSITE & CD Point prevalent
- Page 67 and 68: Table B.11 B.11 Point prevalent rat
- Page 69 and 70: PREVALENCE OF REPORTED ESRD 2005 An
- Page 71 and 72: Reference C Section Patient charact
- Page 73 and 74: PATIENT CHARACTERISTICS 2005 Annual
- Page 75 and 76: PATIENT CHARACTERISTICS 2005 Annual
- Page 77 and 78: PATIENT CHARACTERISTICS 2005 Annual
- Page 79 and 80: PATIENT CHARACTERISTICS 2005 Annual
- Page 81 and 82: PATIENT CHARACTERISTICS 2005 Annual
- Page 83 and 84: ON OUR WEBSITE & CD Mean eGFR by MD
- Page 85 and 86: Table C.14 C.14 Percent distributio
- Page 87 and 88: Reference D Section Treatment modal
- Page 89 and 90: TREATMENT MODALITIES 2005 Annual Da
- Page 91 and 92: TREATMENT MODALITIES 2005 Annual Da
- Page 93 and 94:
TREATMENT MODALITIES 2005 Annual Da
- Page 95 and 96:
TREATMENT MODALITIES 2005 Annual Da
- Page 97 and 98:
TREATMENT MODALITIES 2005 Annual Da
- Page 99 and 100:
TREATMENT MODALITIES 2005 Annual Da
- Page 101 and 102:
TREATMENT MODALITIES 2005 Annual Da
- Page 103 and 104:
TREATMENT MODALITIES 2005 Annual Da
- Page 105 and 106:
TREATMENT MODALITIES 2005 Annual Da
- Page 107 and 108:
ON OUR WEBSITE & CD Incident ESRD p
- Page 109 and 110:
ON OUR WEBSITE & CD Treatment statu
- Page 111 and 112:
TREATMENT MODALITIES 2005 Annual Da
- Page 113 and 114:
ON OUR WEBSITE & CD Living ESRD pat
- Page 115 and 116:
Reference E Section Transplantation
- Page 117 and 118:
TRANSPLANTATION: 2005 Annual Data P
- Page 119 and 120:
TRANSPLANTATION: 2005 Annual Data P
- Page 121 and 122:
TRANSPLANTATION: 2005 Annual Data P
- Page 123 and 124:
ON OUR WEBSITE & CD Median time in
- Page 125 and 126:
TRANSPLANTATION: 2005 Annual Data P
- Page 127 and 128:
TRANSPLANTATION: 2005 Annual Data P
- Page 129 and 130:
ON OUR WEBSITE & CD Renal transplan
- Page 131 and 132:
TRANSPLANTATION: 2005 Annual Data P
- Page 133 and 134:
TRANSPLANTATION: 2005 Annual Data P
- Page 135 and 136:
TRANSPLANTATION: 2005 Annual Data P
- Page 137 and 138:
TRANSPLANTATION: 2005 Annual Data P
- Page 139 and 140:
Reference F Section Transplantation
- Page 141 and 142:
ON OUR WEBSITE & CD 90-day death-ce
- Page 143 and 144:
ON OUR WEBSITE & CD One-year death-
- Page 145 and 146:
ON OUR WEBSITE & CD Two-year death-
- Page 147 and 148:
ON OUR WEBSITE & CD Three-year deat
- Page 149 and 150:
ON OUR WEBSITE & CD Five-year death
- Page 151 and 152:
ON OUR WEBSITE & CD Ten-year graft
- Page 153 and 154:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 155 and 156:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 157 and 158:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 159 and 160:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 161 and 162:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 163 and 164:
Table F.13 F.13 90-day survival wit
- Page 165 and 166:
Table Table F.14 F.14 One-year surv
- Page 167 and 168:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 169 and 170:
Table F.16 F.16 Three-year survival
- Page 171 and 172:
Table Table F.17 F.17 Five-year sur
- Page 173 and 174:
Table F.18 F.18 Ten-year survival w
- Page 175 and 176:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 177 and 178:
Table F.20 F.20 (continued) One-yea
- Page 179 and 180:
Table F.21 F.21 (continued) Two-yea
- Page 181 and 182:
Table Table F.22 F.22 (continued) (
- Page 183 and 184:
Table F.23 F.23 (continued) Five-ye
- Page 185 and 186:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 187 and 188:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 189 and 190:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 191 and 192:
TRANSPLANTATION: 2005 Annual OUTCOM
- Page 193 and 194:
Reference G Section Morbidity & hos
- Page 195 and 196:
ON OUR WEBSITE & CD jkfj Total admi
- Page 197 and 198:
ON OUR WEBSITE & CD Total admission
- Page 199 and 200:
ON OUR WEBSITE & CD Total admission
- Page 201 and 202:
ON OUR WEBSITE & CD Hospital days p
- Page 203 and 204:
ON OUR WEBSITE & CD Hospital days p
- Page 205 and 206:
Table G.11 G.11 Inpatient utilizati
- Page 207 and 208:
Table G.13 G.13 Inpatient utilizati
- Page 209 and 210:
Table G.15 G.15 Inpatient utilizati
- Page 211 and 212:
MORBIDITY & 2005 HOSPITALIZATIONG A
- Page 213 and 214:
MORBIDITY & 2005 HOSPITALIZATIONG A
- Page 215 and 216:
Reference H Section Mortality & cau
- Page 217 and 218:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 219 and 220:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 221 and 222:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 223 and 224:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 225 and 226:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 227 and 228:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 229 and 230:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 231 and 232:
Table H.6 H.6 (continued) Annual mo
- Page 233 and 234:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 235 and 236:
Table H.8 H.8 (continued) Annual mo
- Page 237 and 238:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 239 and 240:
Table H.10 H.10 (continued) Annual
- Page 241 and 242:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 243 and 244:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 245 and 246:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 247 and 248:
Table H.14 H.14 (continued) Annual
- Page 249 and 250:
Table H.16 H.16 Annual mortality ra
- Page 251 and 252:
Table H.17 H.17 (continued) Total p
- Page 253 and 254:
Table H.18 H.18 (continued) MORTALI
- Page 255 and 256:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 257 and 258:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 259 and 260:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 261 and 262:
Table H.22 H.22 (continued) Annual
- Page 263 and 264:
Table H.24 H.24 Annual mortality ra
- Page 265 and 266:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 267 and 268:
Table H.26 H.26 (continued) MORTALI
- Page 269 and 270:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 271 and 272:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 273 and 274:
ON OUR WEBSITE & CD Mortality rates
- Page 275 and 276:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 277 and 278:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 279 and 280:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 281 and 282:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 283 and 284:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 285 and 286:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 287 and 288:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 289 and 290:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 291 and 292:
MORTALITY & CAUSES OF DEATH 2005 An
- Page 293 and 294:
Reference I Section Patient surviva
- Page 295 and 296:
I PATIENT SURVIVAL 2005 Annual Data
- Page 297 and 298:
I PATIENT SURVIVAL 2005 Annual Data
- Page 299 and 300:
I PATIENT SURVIVAL 2005 Annual Data
- Page 301 and 302:
I PATIENT SURVIVAL 2005 Annual Data
- Page 303 and 304:
I PATIENT SURVIVAL 2005 Annual Data
- Page 305 and 306:
I PATIENT SURVIVAL 2005 Annual Data
- Page 307 and 308:
I PATIENT SURVIVAL 2005 Annual Data
- Page 309 and 310:
I PATIENT SURVIVAL 2005 Annual Data
- Page 311 and 312:
Table I.8 (continued) Table Inciden
- Page 313 and 314:
I PATIENT SURVIVAL 2005 Annual Data
- Page 315 and 316:
I PATIENT SURVIVAL 2005 Annual Data
- Page 317 and 318:
I PATIENT SURVIVAL 2005 Annual Data
- Page 319 and 320:
I PATIENT SURVIVAL 2005 Annual Data
- Page 321 and 322:
I PATIENT SURVIVAL 2005 Annual Data
- Page 323 and 324:
I PATIENT SURVIVAL 2005 Annual Data
- Page 325 and 326:
I PATIENT SURVIVAL 2005 Annual Data
- Page 327 and 328:
I PATIENT SURVIVAL 2005 Annual Data
- Page 329 and 330:
I PATIENT SURVIVAL 2005 Annual Data
- Page 331 and 332:
I PATIENT SURVIVAL 2005 Annual Data
- Page 333 and 334:
I PATIENT SURVIVAL 2005 Annual Data
- Page 335 and 336:
I PATIENT SURVIVAL 2005 Annual Data
- Page 337 and 338:
I PATIENT SURVIVAL 2005 Annual Data
- Page 339 and 340:
I PATIENT SURVIVAL 2005 Annual Data
- Page 341 and 342:
I PATIENT SURVIVAL 2005 Annual Data
- Page 343 and 344:
I PATIENT SURVIVAL 2005 Annual Data
- Page 345 and 346:
I PATIENT SURVIVAL 2005 Annual Data
- Page 347 and 348:
I PATIENT SURVIVAL 2005 Annual Data
- Page 349 and 350:
I PATIENT SURVIVAL 2005 Annual Data
- Page 351 and 352:
I PATIENT SURVIVAL 2005 Annual Data
- Page 353 and 354:
I PATIENT SURVIVAL 2005 Annual Data
- Page 355 and 356:
I PATIENT SURVIVAL 2005 Annual Data
- Page 357 and 358:
I PATIENT SURVIVAL 2005 Annual Data
- Page 359 and 360:
I PATIENT SURVIVAL 2005 Annual Data
- Page 361 and 362:
I PATIENT SURVIVAL 2005 Annual Data
- Page 363 and 364:
I PATIENT SURVIVAL 2005 Annual Data
- Page 365 and 366:
I PATIENT SURVIVAL 2005 Annual Data
- Page 367 and 368:
I PATIENT SURVIVAL 2005 Annual Data
- Page 369 and 370:
I PATIENT SURVIVAL 2005 Annual Data
- Page 371 and 372:
Reference J Section Provider charac
- Page 373 and 374:
Table J.1 J.1 Certified dialysis &
- Page 375 and 376:
Table J.5 J.5 Dialysis & transplant
- Page 377 and 378:
PROVIDER CHARACTERISTICS 2005 Annua
- Page 379 and 380:
Table J.13 J.13 Dialysis patients:
- Page 381 and 382:
PROVIDER CHARACTERISTICS JReference
- Page 383 and 384:
Reference K Section Medicare costs
- Page 385 and 386:
Table K.1 K.1 Total Medicare costs
- Page 387 and 388:
MEDICARE COSTS FOR ESRD 2005 Annual
- Page 389 and 390:
MEDICARE COSTS FOR ESRD 2005 Annual
- Page 391 and 392:
MEDICARE COSTS FOR ESRD 2005 Annual
- Page 393 and 394:
MEDICARE COSTS FOR ESRD 2005 Annual
- Page 395 and 396:
MEDICARE COSTS FOR ESRD 2005 Annual
- Page 397 and 398:
MEDICARE COSTS FOR ESRD 2005 Annual
- Page 399 and 400:
MEDICARE COSTS FOR ESRD 2005 Annual
- Page 401 and 402:
Reference L Section Vascular access
- Page 403 and 404:
Table L.1 L.1 Catheter insertions i
- Page 405 and 406:
Table L.3 L.3 Graft insertions in p
- Page 407 and 408:
VASCULAR 2005 Annual Data ACCESSL R
- Page 409 and 410:
VASCULAR 2005 Annual Data ACCESSL R
- Page 411 and 412:
VASCULAR 2005 Annual Data ACCESSL R
- Page 413 and 414:
VASCULAR 2005 Annual Data ACCESSL R
- Page 415 and 416:
VASCULAR 2005 Annual Data ACCESSL R
- Page 417 and 418:
VASCULAR 2005 Annual Data ACCESSL R
- Page 419 and 420:
VASCULAR 2005 Annual Data ACCESSL R
- Page 421 and 422:
Table L.12 L.12 Arteriovenous fistu
- Page 423 and 424:
Reference M Section Census populati
- Page 425 and 426:
CENSUS POPULATIONS 2005 Annual Data
- Page 427 and 428:
CENSUS POPULATIONS 2005 Annual Data
- Page 429 and 430:
CENSUS POPULATIONS 2005 Annual Data
- Page 431 and 432:
CENSUS POPULATIONS 2005 Annual Data
- Page 433 and 434:
Table M.2 M.2 Resident population e